ArticleTranslational oncology2026
Circulating low-density neutrophils as biomarkers of resistance to first-line anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research trends in cytokine regulation of immunotherapy in non-small cell lung cancer: a bibliometric and BERTopic analysis from 2015 to 2025.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have improved outcomes in advanced non-small cell lung cancer (NSCLC), however reliable predictive biomarkers are lacking. Our group previously reported an association between high levels of circulating low-density neutrophils (LDNs) and resistance to ICI monotherapy. We present updated results, including a validation cohort, proteomic characterization of LDNs, and in vivo experiments exploring mechanisms of resistance.
methodsNSCLC patients treated with first line ICI monotherapy (n=60) or combined with chemotherapy (CT+ICI) (n=60) were recruited. LDNs were quantified by flow cytometry and correlated with clinical outcomes. Phenotypes of LDNs and conventional neutrophils were characterised by flow cytometry and quantitative proteomics. Plasma cytokine measurements and in vivo experiments were conducted to assess the role of LDNs in ICI resistance.
resultsHigh baseline LDN levels were significantly associated with primary resistance to ICI monotherapy, with patients showing an overall response rate (ORR) of 17% vs 50% (p=0.04) and median progression free survival (mPFS) of 2.3 months vs 21.8 months (p < 0.001). No such association was seen in patients treated with CT+ICI, showing a LDN depletion in responders. LDNs exhibited an aged phenotype and distinct proteomic profile. Plasma from high-LDN patients showed elevated myeloid-expansion (M-CSF, IL1β) and inflammatory cytokines (CXCL9, IL-25). Depletion of Gr1+ population enhanced response to ICI and CT+ICI in the Lewis Lung Carcinoma (LLC) model with high LDNs.
conclusionHigh baseline LDNs predict resistance to ICI monotherapy in NSCLC and combination with chemotherapy may overcome this resistance. Additional therapeutic strategies targeting LDNs could enhance immunotherapy efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.